Page 467 - Read Online

Abbas et al. Hepatoma Res 2018;4:43 I http://dx.doi.org/10.20517/2394-5079.2018.26 Page 5 of 8

Among patients treated with DAA, SVR is associated with a considerable reduction in the risk of HCC.
However, in patients with SVR, the absolute risk of HCC remains high in patients with established cirrhosis .
[62]

CONCLUSION
Hepatitis C accounts for the majority of the cases of HCC in many parts of the world. HCC typically
occurs in patients with advanced hepatic fibrosis or cirrhosis in the setting of chronic inflammatory state
induced by HCV. Clinical and epidemiologic studies have identified host and viral factors associated with
HCC development in patients with HCV infection. Direct-acting antiviral drugs do not increase the risk
of developing HCC. Sustained virological response to the antiviral therapy results in significantly more
favorable long-term outcomes.

DECLARATIONS
Authors’ contributions
Both authors contributed by literature review and manuscript writing, editing and review.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
2. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47 Suppl:S2-6.
3. Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J
Gastroenterol 2013;48:681-8.
4. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006;80:1197-213.
5. Maki A, Kono H, Gupta M, Asakawa M, Suzuki T, Matsuda M, Fujii H, Rusyn I. Predictive power of biomarkers of oxidative stress and
inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol 2007;14:1182-90.
6. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. The core protein
of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065-7.
7. Mitchell JK, Lemon SM, McGivern DR. How do persistent infections with hepatitis C virus cause liver cancer? Curr Opin Virol
2015;14:101-8.
8. Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio R, Morio K, Kan H, Fujino H,
Kobayashi T, Masaki K, Ono A, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Hayes CN, Miki D, Ochi H, Chayama K.
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus
ribavirin and direct-acting antiviral therapy. PLoS One 2017;12:e0182710.
9. Matsuura K, Sawai H, Ikeo K, Ogawa S, Iio E, Isogawa M, Shimada N, Komori A, Toyoda H, Kumada T, Namisaki T, Yoshiji H,